FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.

Abstract excerpt

Internal tandem duplications of the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most frequent gene mutations in acute myeloid leukemia (AML) and are associated with poor clinical outcome. The remission rate is high with intensive chemotherapy, but most patients eventually relapse. During the last decade, FLT3 mutations have emerged as an attractive target for a molecularly specific treatment strategy....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Disease
• Share to Drug Resistance, Neoplasm
• Share to fms-Like Tyrosine Kinase 3